

EFNS guidelines on diagnosis and management of neuro

European Journal of Neurology

17, 1019-1032

DOI: 10.1111/j.1468-1331.2010.03066.x

Citation Report

#	ARTICLE	IF	CITATIONS
1	Anti-aquaporin-4 antibodies in Devic's neuromyelitis optica: therapeutic implications. Therapeutic Advances in Neurological Disorders, 2010, 3, 311-321.	3.5	28
3	Anti-AQP4-Antikörper als Biomarker zur Früherkennung von Neuromyelitis Optica-Spektrum-Erkrankungen / AQP4-IgG antibodies as biomarkers for early diagnosis of neuromyelitis optica spectrum disorders. Laboratoriums Medizin, 2010, 34, 337-342.	0.6	0
4	Aquaporin 4 antibody positive central nervous system autoimmunity and multiple sclerosis are characterized by a distinct profile of antibodies to herpes viruses. Neurochemistry International, 2010, 57, 662-667.	3.8	15
5	Historia de la enfermedad de Devic. Revista Colombiana De Reumatología, 2011, 18, 271-284.	0.1	0
6	Longitudinal extensive transverse myelitis – it's not all neuromyelitis optica. Nature Reviews Neurology, 2011, 7, 688-698.	10.1	141
7	Systemic sclerosis in aquaporin-4 antibody-positive longitudinally extensive transverse myelitis. Journal of the Neurological Sciences, 2011, 303, 139-141.	0.6	21
8	Bilateral optic neuritis in a 26-year-old man with common variable immunodeficiency: a case report. Journal of Medical Case Reports, 2011, 5, 319.	0.8	9
9	Azathioprine. Neurology, 2011, 77, 659-666.	1.1	236
10	Spinal cord tumor versus transverse myelitis. Spine Journal, 2011, 11, 1143-1145.	1.3	16
11	The limited demyelinating diseases: the voyage of optic neuritis and transverse myelitis to multiple sclerosis and neuromyelitis. Expert Review of Neurotherapeutics, 2011, 11, 451-462.	2.8	3

12

#	ARTICLE	IF	CITATIONS
21	Current and future treatment approaches for neuromyelitis optica. <i>Therapeutic Advances in Neurological Disorders</i> , 2011, 4, 111-121.	3.5	73
22	Impact of rituximab on relapse rate and disability in neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1225-1230.	3.0	141
23	Antibodies against aquaporin-4 in neuromyelitis optica: distinction between recurrent and monophasic patients. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1527-1530.	3.0	39
24	A population-based study of neuromyelitis optica in Caucasians. <i>Neurology</i> , 2011, 76, 1589-1595.	1.1	240
25	Neuromyelitis Optica Spectrum Disease with Positive Autoimmune Indices: A Case Report and Review of the Literature. <i>Case Reports in Medicine</i> , 2011, 2011, 1-4.	0.7	7
26	Clinical approach to optic neuritis: pitfalls, red flags and differential diagnosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2011, 4, 123-134.	3.5	69
27	Neuromyelitis Optica: An Antibody-Mediated Disorder of the Central Nervous System. <i>Neurology Research International</i> , 2012, 2012, 1-13.	1.3	64
28	Value of NMO-IgG determination at the time of presentation as CIS. <i>Neurology</i> , 2012, 78, 1608-1611.	1.1	16
29	Blood-Brain Barrier Disruption is More Severe in Neuromyelitis Optica than in Multiple Sclerosis and Correlates with Clinical Disability. <i>Journal of International Medical Research</i> , 2012, 40, 1483-1491.	1.0	43
30	Antibodies to MOG in NMO. <i>Neurology</i> , 2012, 79, 1198-1199.	1.1	9
31	Considerations in the design of clinical trials for relapsing multiple sclerosis. <i>Clinical Investigation</i> , 2012, 2, 1073-1083.	0.0	5
32	Plasma Exchange in Severe Attacks of Neuromyelitis Optica. <i>Multiple Sclerosis International</i> , 2012, 2012, 1-9.	0.8	75
33	Lack of Response to Pulse Cyclophosphamide in Neuromyelitis Optica. <i>Archives of Neurology</i> , 2012, 69, 938.	4.5	45
34	Semiquantitative measurement of aquaporin-4 antibodies as a possible surrogate marker of neuromyelitis optica spectrum disorders with systemic autoimmune diseases. <i>Modern Rheumatology</i> , 2012, 22, 676-684.	1.8	14
35	Autoantibody Associated Disorders of the CNS in Children: The List Keeps Growing. <i>Canadian Journal of Neurological Sciences</i> , 2012, 39, 129-131.	0.5	1
36	Disease-specific therapy of idiopathic inflammatory demyelinating disorders. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 1113-1124.	2.8	2
37	Anti-aquaporin-4 antibody-positive recurrent isolated optic neuritis and primary Sjögren's syndrome. <i>Journal of Neurology</i> , 2012, 259, 1740-1741.	3.6	4
38	Neuromyelitis optica: atypical clinic presentation. <i>Neurological Sciences</i> , 2012, 33, 1439-1442.	1.9	1

#	ARTICLE	IF	CITATIONS
39	Diagnostic approach in optic neuropathy. <i>Revue Neurologique</i> , 2012, 168, 691-696.	1.5	4
40	Immunotherapies in Neurologic Disorders. <i>Medical Clinics of North America</i> , 2012, 96, 497-523.	2.5	7
41	The unfolding tale of an unusual brain stem syndrome. <i>Practical Neurology</i> , 2012, 12, 55-59.	1.1	0
42	Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4. <i>Multiple Sclerosis Journal</i> , 2012, 18, 578-586.	3.0	65
43	Acute Demyelinating Disorders: Emergencies and Management. <i>Neurologic Clinics</i> , 2012, 30, 285-307.	1.8	12
44	The Spectrum of Neuromyelitis Optica (NMO) in Childhood. <i>Journal of Child Neurology</i> , 2012, 27, 1437-1447.	1.4	38
45	Recurrent acute rhombencephalomyelitis in an adult or neuromyelitis optica? Presentation of a case. <i>Neurologia (English Edition)</i> , 2012, 27, 154-160.	0.4	1
46	A practical guide to the treatment of neuromyelitis optica. <i>Practical Neurology</i> , 2012, 12, 209-214.	1.1	51
47	Cerebrospinal Fluid BAFF and APRIL Levels in Neuromyelitis Optica and Multiple Sclerosis Patients During Relapse. <i>Journal of Clinical Immunology</i> , 2012, 32, 1007-1011.	3.8	72
48	What Started This? Debilitating Longitudinally-extensive Myelitis. <i>American Journal of Medicine</i> , 2012, 125, 1071-1073.	1.5	2
49	A 72-year-old patient with neuromyelitis optica (NMO) spectrum disorder: A case report. <i>European Geriatric Medicine</i> , 2012, 3, 240-241.	2.8	0
50	Spectrum disorder of neuromyelitis optica in a patient presenting with intractable vomiting and hiccups, transverse myelitis and acute encephalopathy. <i>Journal of Clinical Neuroscience</i> , 2012, 19, 1576-1578.	1.5	12
51	Visual evoked potentials in early diagnosis of demyelinating diseases – a case report of Devic's disease. <i>Medical Science Monitor</i> , 2012, 18, CS82-CS84.	1.1	3
52	Subacute sclerosing panencephalitis presenting as neuromyelitis optica. <i>BMJ Case Reports</i> , 2012, 2012, bcr2012006764-bcr2012006764.	0.5	4
53	Neuromyelitis optica: multiple sclerosis variant or independent disease?. <i>International Journal of Ophthalmic Practice</i> , 2012, 3, 114-121.	0.0	0
54	The differential diagnosis of longitudinally extensive transverse myelitis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 271-285.	3.0	126
55	Anti-Aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. <i>Annals of Neurology</i> , 2012, 71, 314-322.	5.3	232
56	Diagnostic approach of patients with longitudinally extensive transverse myelitis. <i>Acta Neurologica Belgica</i> , 2012, 112, 39-43.	1.1	7

#	ARTICLE	IF	CITATIONS
57	Diagnosis of neuromyelitis optica (NMO) spectrum disorders: is MRI obsolete?. <i>Neuroradiology</i> , 2012, 54, 279-285.	2.2	41
59	Conventional brain MRI in neuromyelitis optica. <i>European Journal of Neurology</i> , 2012, 19, 812-819.	3.3	46
60	Immune Mediated Diseases and Immune Modulation in the Neurocritical Care Unit. <i>Neurotherapeutics</i> , 2012, 9, 99-123.	4.4	14
61	Monoclonal antibodies in neuroinflammatory diseases. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 831-846.	3.1	14
62	Treatment of NMO relapse in the elderly: rituximab when plasma exchange fails?. <i>Acta Neurologica Belgica</i> , 2013, 113, 335-336.	1.1	5
63	Variants in the promoter region of CYP7A1 are associated with neuromyelitis optica but not with multiple sclerosis in the Han Chinese population. <i>Neuroscience Bulletin</i> , 2013, 29, 525-530.	2.9	16
64	Fulminant Demyelinating Diseases. <i>Neurohospitalist</i> , The, 2013, 3, 81-91.	0.8	51
65	Monitoring neuromyelitis optica activity. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 989-999.	2.8	1
66	Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1243-1253.	4.1	10
67	Aquaporins, anti-aquaporin-4 autoantibodies and neuromyelitis optica. <i>Clinica Chimica Acta</i> , 2013, 415, 350-360.	1.1	8
68	Neuromyelitis Optica. <i>Neurologic Clinics</i> , 2013, 31, 139-152.	1.8	29
69	Treatment of multiple sclerosis and neuromyelitis optica in children and adolescents. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, S21-S29.	1.4	12
70	Central nervous system inflammatory demyelinating disorders among Hong Kong Chinese. <i>Journal of Neuroimmunology</i> , 2013, 262, 100-105.	2.3	20
71	Seropositive Neuromyelitis Optica: A Pediatric Case Report and 6-Year Follow-Up. <i>Pediatric Neurology</i> , 2013, 49, 198-202.	2.1	2
72	Neuromielitis Óptica: actualización clínica y terapéutica. <i>Neurología Argentina</i> , 2013, 5, 259-269.	0.3	3
74	A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple) TJ ETQq1 1 0.784314 rgBT /Overl	3.0	7
75	Early treatment of inflammatory demyelinating disease. <i>Nature Reviews Neurology</i> , 2013, 9, 246-247.	10.1	0
76	Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases. <i>Journal of the Neurological Sciences</i> , 2013, 328, 77-82.	0.6	22

#	ARTICLE	IF	CITATIONS
77	Brain-Reactive Antibodies and Disease. Annual Review of Immunology, 2013, 31, 345-385.	21.8	115
78	Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders. Journal of the Neurological Sciences, 2013, 324, 38-39.	0.6	45
79	Unusual Manifestations of Pediatric Neuromyelitis Optica. Journal of Child Neurology, 2013, 28, 658-662.	1.4	8
80	Increased plasma levels of pentraxin 3 in patients with multiple sclerosis and neuromyelitis optica. Multiple Sclerosis Journal, 2013, 19, 926-931.	3.0	30
81	Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology, 2013, 80, 1330-1337.	1.1	189
82	Meningoencephalitis as an initial manifestation of neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal, 2013, 19, 639-643.	3.0	15
83	Optimizing the management of neuromyelitis optica and spectrum disorders in resource poor settings: Experience from the Mangalore demyelinating disease registry. Annals of Indian Academy of Neurology, 2013, 16, 572.	0.5	21
84	Safety of MF59-Adjuvanted Influenza Vaccination in the Elderly: Results of a Comparative Study of MF59-Adjuvanted Vaccine Versus Nonadjuvanted Influenza Vaccine in Northern Italy. American Journal of Epidemiology, 2013, 178, 1139-1145.	3.4	36
85	Antibody response against gastrointestinal antigens in demyelinating diseases of the central nervous system. European Journal of Neurology, 2013, 20, 1492-1495.	3.3	49
86	Long-term MRI findings in neuromyelitis optica: seropositive versus seronegative patients. European Journal of Neurology, 2013, 20, 781-787.	3.3	33
87	Quantitative MRI Analysis of the Brain after Twenty-Two Years of Neuromyelitis Optica Indicates Damage Focal Tissue. European Neurology, 2013, 69, 221-225.	1.4	3
88	Efficacy of methylprednisolone pulse therapy for acute relapse in Japanese patients with multiple sclerosis and neuromyelitis optica: A multicenter retrospective analysis – 1. Whole group analysis. Clinical and Experimental Neuroimmunology, 2013, 4, 305-317.	1.0	9
89	Efficacy of Intravenous Cyclophosphamide Therapy for Neuromyelitis Optica Spectrum Disorder. Internal Medicine, 2013, 52, 969-972.	0.7	53
91	Patients with neuromyelitis optica have a more severe disease than patients with relapsing-remitting multiple sclerosis, including higher risk of dying of a demyelinating disease. Arquivos De Neuro-Psiquiatria, 2013, 71, 275-279.	0.8	19
92	Neuromyelitis Optica in Austria in 2011: To Bridge the Gap between Neuroepidemiological Research and Practice in a Study Population of 8.4 Million People. PLoS ONE, 2013, 8, e79649.	2.5	55
93	Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis. PLoS ONE, 2013, 8, e66151.	2.5	162
94	Neuromyelitis Optica Mimicking Intramedullary Tumor. Journal of Korean Neurosurgical Society, 2013, 53, 316.	1.2	6
95	Clinical Efficacy of Plasmapheresis in Patients with Neuromyelitis Optica Spectrum Disorder and		

#	ARTICLE	IF	CITATIONS
96	A Case of Systemic Lupus Erythematosus with Myelitis and Recurrent Neuromyelitis Optica. Journal of Rheumatic Diseases, 2013, 20, 64.	1.1	1
97	Clinical Correlations of Motor and Somatosensory Evoked Potentials in Neuromyelitis Optica. PLoS ONE, 2014, 9, e113631.	2.5	7
98	Neuromyelitis Optica Spectrum Disorder in a Chinese Woman with Ocular Myasthenia Gravis: First Reported Case in the Chinese Population. Neuro-Ophthalmology, 2014, 38, 140-144.	1.0	2
99	Treatment options for atypical optic neuritis. Indian Journal of Ophthalmology, 2014, 62, 982.	1.1	12
100	A clinical and radiological profile of neuromyelitis optica and spectrum disorders in an Indian cohort. Annals of Indian Academy of Neurology, 2014, 17, 77.	0.5	24
101	Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system. Clinical and Experimental Immunology, 2014, 176, 135-148.	2.6	8
102	Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica. Annals of Neurology, 2014, 75, 447-453.	5.3	43
103	Neuromyelitis optica spectrum disorders accompanying subarachnoid hemorrhage and reversible white matter lesions. Neurology and Clinical Neuroscience, 2014, 2, 10-12.	0.4	3
104	Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate. BMC Neurology, 2014, 14, 51.	1.8	40
105	Comparison between the cranial magnetic resonance imaging features of neuromyelitis optica spectrum disorder versus multiple sclerosis in Taiwanese patients. BMC Neurology, 2014, 14, 218.	1.8	19
106	Etiologic Spectrum and Prognosis of Longitudinally Extensive Transverse Myelopathies. European Neurology, 2014, 72, 86-94.	1.4	22
107	The Treatment of Neuromyelitis Optica. Journal of Neuro-Ophthalmology, 2014, 34, 70-82.	0.8	41
108	Clinical Manifestations and Spinal Cord Magnetic Resonance Imaging Findings in Chinese Neuromyelitis Optica Patients. European Neurology, 2014, 71, 35-41.	1.4	10
109	NMO spectrum disorders: how wide is the spectrum?. Multiple Sclerosis Journal, 2014, 20, 1417-1419.	3.0	2
110	“Spinal amaurosis” (1841). On the early contribution of Edward Hocken to the concept of neuromyelitis optica. Journal of Neurology, 2014, 261, 400-404.	3.6	8
111	Overlapping demyelinating syndromes and anti-“N-methyl-D-aspartate receptor encephalitis. Annals of Neurology, 2014, 75, 411-428.	5.3	405
112	Optic neuritis. Lancet Neurology, The, 2014, 13, 83-99.	10.2	463
113	Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). Journal of Neurology, 2014, 261, 1-16.	3.6	494

#	ARTICLE	IF	CITATIONS
114	Desarrollos del espectro de la neuromielitis óptica: estudio retrospectivo multicéntrico. Neurología Argentina, 2014, 6, 207-211.	0.3	0
115	Neuro-ophthalmology update. Journal of Neurology, 2014, 261, 1251-1256.	3.6	4
116	IL-17 and Glutamate Excitotoxicity in the Pathogenesis of Multiple Sclerosis. Scandinavian Journal of Immunology, 2014, 79, 181-186.	2.7	77
117	Cell-surface central nervous system autoantibodies: Clinical relevance and emerging paradigms. Annals of Neurology, 2014, 76, 168-184.	5.3	159
118	Multiple sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 269-290.	1.8	98
119	Pearls & Oysters: A cause of intractable vomiting. Neurology, 2014, 83, e141-4.	1.1	1
120	The role of imaging in diagnosing neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2014, 3, 284-293.	2.0	11
121	A systematic analysis of the complement pathways in patients with neuromyelitis optica indicates alteration but no activation during remission. Molecular Immunology, 2014, 57, 200-209.	2.2	19
122	The neurology of Sjögren's syndrome and the rheumatology of peripheral neuropathy and myelitis. Practical Neurology, 2014, 14, 14-22.	1.1	70
123	Biomarkers for Multiple Sclerosis. Internal Medicine, 2014, 53, 361-365.	0.7	36
124	Systemic Lupus Erythematosus (SLE) Complicated by Neuromyelitis Optica (NMO – Devic's Disease): Clinic-Pathological Report and Review of the Literature. Clinical Medicine Insights: Case Reports, 2014, 7, CCRep.S15177.	0.7	23
125	Antibody biomarkers in CNS demyelinating diseases – a long and winding road. European Journal of Neurology, 2015, 22, 1162-1168.	3.3	31
126	Placebo controlled trials in neuromyelitis optica are needed and ethical. Multiple Sclerosis and Related Disorders, 2015, 4, 536-545.	2.0	10
127	The Urine Proteome Profile Is Different in Neuromyelitis Optica Compared to Multiple Sclerosis: A Clinical Proteome Study. PLoS ONE, 2015, 10, e0139659.	2.5	15
128	Profile of neuromyelitis optica and spectrum disorders in an Indian cohort. Journal of Neurosciences in Rural Practice, 2015, 6, 295-296.	0.8	0
129	Placebo studies should not be undertaken in NMO – Yes. Multiple Sclerosis Journal, 2015, 21, 689-691.	3.0	1
130	Longitudinally extensive transverse myelitis in systemic lupus erythematosus: Case report and review of the literature. Clinical Neurology and Neurosurgery, 2015, 129, 57-61.	1.4	22
132	Neuromyelitis optica spectrum disorders associated with other autoimmune diseases. Rheumatology International, 2015, 35, 243-253.	3.0	34

#	ARTICLE	IF	CITATIONS
133	Autologous hematopoietic stem cell transplantation in neuromyelitis optica: A registry study of the EBMT Autoimmune Diseases Working Party. Multiple Sclerosis Journal, 2015, 21, 189-197.	3.0	56
134	Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica. Journal of Clinical Neuroscience, 2015, 22, 1178-1182.	1.5	40
135	Neuromyelitis Optica: Atypical Clinical and Neuroradiological Presentation. Neuroradiology Journal, 2015, 28, 41-45.	1.2	5
136	Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica. Journal of Neuroimmunology, 2015, 282, 92-96.	2.3	40
137	Challenges and opportunities in designing clinical trials for neuromyelitis optica. Neurology, 2015, 84, 1805-1815.	1.1	39
138	Challenges in randomized controlled trials and emerging multiple sclerosis therapeutics. Neuroscience Bulletin, 2015, 31, 745-754.	2.9	6
139	Atypical Optic Neuritis. Current Neurology and Neuroscience Reports, 2015, 15, 76.	4.2	18
140	Embarazo y posparto en una paciente con neuromielitis Óptica de Devic y lupus eritematoso sistémico, y revisión de la literatura. Neurología Argentina, 2015, 7, 120-123.	0.3	0
141	Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Multiple Sclerosis Journal, 2015, 21, 866-874.	3.0	241
142	Imaging of multiple sclerosis and related acquired demyelinating disorders in childhood. Journal of Pediatric Neuroradiology, 2015, 02, 057-072.	0.1	1
143	Intractable Hiccups and Nausea as a Principal Symptom of Neuromyelitis Optica in a Patient with a Prior History of Miller-Fisher Syndrome. Journal of General and Family Medicine, 2016, 17, 99-104.	0.8	0
144	Unusual Presentation of Unilateral Isolated Probable Lyme Optic Neuritis. Case Reports in Neurological Medicine, 2016, 2016, 1-4.	0.4	8
145	Acute Respiratory Failure due to Neuromyelitis Optica Treated Successfully with Plasmapheresis. Case Reports in Pulmonology, 2016, 2016, 1-3.	0.3	6
146	Neuromyelitis optica and Wernicke encephalopathy share the similar imagings, any correlations?. Radiology of Infectious Diseases, 2016, 3, 79-83.	0.0	3
147	Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort. Neurology, 2016, 86, 1683-1691.	1.1	149
148	Current and future immunotherapy targets in autoimmune neurology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 133, 511-536.	1.8	4
149	Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: A prospective cohort study. Journal of the Neurological Sciences, 2016, 370, 224-228.	0.6	56
150	How long does it take to diagnose patients with neuromyelitis optica (NMO) using the 2006 diagnostic criteria?. Multiple Sclerosis and Related Disorders, 2016, 9, 14-16.	2.0	5

#	ARTICLE	IF	CITATIONS
151	The role of AQP4 in neuromyelitis optica: More answers, more questions. <i>Journal of Neuroimmunology</i> , 2016, 298, 63-70.	2.3	37
152	Early initiation of steroid pulse therapy for neuromyelitis optica in an emergency room setting. <i>Acute Medicine & Surgery</i> , 2016, 3, 171-173.	1.2	0
153	Epidemiology of Multiple Sclerosis. <i>Neurologic Clinics</i> , 2016, 34, 919-939.	1.8	214
154	Quotient of cerebrospinal fluid/serum immunoglobulin G as a predictive factor for nonresponders to intravenous methylprednisolone therapy in patients with relapsing neuromyelitis optica spectrum disorder: Implication for early initiation of plasmapheresis. <i>Clinical and Experimental Neuroimmunology</i> , 2016, 7, 272-280.	1.0	2
155	Neuromyelitis Optica (Devic's Syndrome): an Appraisal. <i>Current Rheumatology Reports</i> , 2016, 18, 54.	4.7	13
156	Placebo-controlled study in neuromyelitis optica—Ethical and design considerations. <i>Multiple Sclerosis Journal</i> , 2016, 22, 862-872.	3.0	63
157	Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study. <i>Journal of Neurology</i> , 2016, 263, 1727-1735.	3.6	45
158	Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. <i>Annals of Neurology</i> , 2016, 79, 206-216.	5.3	315
159	Seronegative neuromyelitis optica presenting with life-threatening respiratory failure. <i>Journal of Spinal Cord Medicine</i> , 2016, 39, 734-736.	1.4	4
160	Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study. <i>Journal of Neurology</i> , 2016, 263, 575-582.	3.6	53
161	Nontraumatic spinal cord injury at the neurological intensive care unit: spectrum, causes of admission and predictors of mortality. <i>Therapeutic Advances in Neurological Disorders</i> , 2016, 9, 85-94.	3.5	20
162	Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders. <i>Neurotherapeutics</i> , 2016, 13, 70-83.	4.4	90
163	Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1337-1348.	3.0	32
164	Change in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus: A preliminary study. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1192-1201.	3.0	21
165	Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. <i>Multiple Sclerosis Journal</i> , 2016, 22, 511-519.	3.0	76
166	Effects of early using azathioprine in the acute phase in neuromyelitis optica spectrum disorder. <i>International Journal of Neuroscience</i> , 2017, 127, 508-515.	1.6	1
167	Comparison of 6-mercaptopurine with 6-thioguanine for the analysis of thiopurine methyltransferase activity in human erythrocyte by LC-MS/MS. <i>Biomedical Chromatography</i> , 2017, 31, e3959.	1.7	4
168	Elevated CXCL13 and BAFF levels in neuromyelitis optica during remission. <i>Brain and Behavior</i> , 2017, 7, e00648.	2.2	6

#	ARTICLE	IF	CITATIONS
169	Detection of Thyroid Abnormalities in Aquaporin-4 Antibodyâ€“Seropositive Optic Neuritis Patients. <i>Journal of Neuro-Ophthalmology</i> , 2017, 37, 24-29.	0.8	1
170	Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 639-647.	1.9	123
171	Neuromyelitis optica and neuromyelitis optica spectrum disorders. <i>Current Opinion in Neurology</i> , 2017, 30, 208-215.	3.6	38
172	A curious case of neuromyelitis optica spectrum disorder co-existing with idiopathic intracranial hypertension. <i>Journal of Clinical Neuroscience</i> , 2017, 41, 104-106.	1.5	3
173	The characteristics of spinal imaging in different types of demyelinating diseases. <i>Journal of the Neurological Sciences</i> , 2017, 372, 138-143.	0.6	12
174	Neurological Complications of Sj�gren��s Syndrome: Diagnosis and Management. <i>Current Treatment Options in Rheumatology</i> , 2017, 3, 275-288.	1.4	45
175	Peduncular Hallucinosis and Autonomic Dysfunction in Anti-Aquaporin-4 Antibody Syndrome. <i>Cognitive and Behavioral Neurology</i> , 2017, 30, 116-124.	0.9	7
176	Neuromyelitis optica spectrum disorders: An experience from tertiary care hospital of North��West India. <i>Indian Journal of Medical Specialities</i> , 2017, 8, 192-196.	0.1	2
177	Immunoadsorption in neurological disorders. <i>Transfusion and Apheresis Science</i> , 2017, 56, 671-676.	1.0	33
178	Neuromyelitis Optica. <i>Rheumatic Disease Clinics of North America</i> , 2017, 43, 579-591.	1.9	42
179	Patient perspectives on neuromyelitis optica spectrum disorders: Data from the PatientsLikeMe online community. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 17, 116-122.	2.0	43
180	Hiccups as Herald: Neuromyelitis Optica Spectrum Disorder. <i>American Journal of Medicine</i> , 2017, 130, 1055-1058.	1.5	2
181	Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1377-1384.	3.0	89
182	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up. <i>Journal of the Neurological Sciences</i> , 2017, 372, 92-96.	0.6	25
184	Herpes Simplex Virus Type 2 Myelitis: Case Report and Review of the Literature. <i>Frontiers in Neurology</i> , 2017, 8, 199.	2.4	26
185	Relationship between Azathioprine metabolites and therapeutic efficacy in Chinese patients with neuromyelitis optica spectrum disorders. <i>BMC Neurology</i> , 2017, 17, 130.	1.8	6
186	Acute Clinical Worsening after Steroid Administration in Cervical Myelitis May Reveal a Subdural Arteriovenous Fistula. <i>Case Reports in Neurology</i> , 2017, 8, 234-242.	0.7	10
187	Rituximab therapy in pemphigus and other autoantibody-mediated diseases. <i>F1000Research</i> , 2017, 6, 83.	1.6	23

#	ARTICLE	IF	CITATIONS
188	Severe course of neuromyelitis optica in a female patient with chronic C hepatitis. <i>Neurologia i Neurochirurgia Polska</i> , 2018, 52, 397-400.	1.2	3
189	Incidence of neuromyelitis optica spectrum disorder in the Central Denmark Region. <i>Acta Neurologica Scandinavica</i> , 2018, 137, 582-588.	2.1	17
190	Evaluation of comorbidities and health care resource use among patients with highly active neuromyelitis optica. <i>Journal of the Neurological Sciences</i> , 2018, 384, 96-103.	0.6	40
191	Beneficial effect of plasma exchange in acute attack of neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 115-121.	2.0	30
192	A Young Woman With Sudden Urinary Retention and Sensory Deficits. <i>Arthritis Care and Research</i> , 2018, 70, 635-642.	3.4	3
193	Epidemiología de la neuromielitis óptica en Costa Rica: un análisis multicéntrico. <i>Neurologia Argentina</i> , 2018, 10, 185-193.	0.3	2
194	Detection of aquaporin-4 antibodies for patients with CNS inflammatory demyelinating diseases other than typical MS in Lithuania. <i>Brain and Behavior</i> , 2018, 8, e01129.	2.2	5
195	Intractable vomiting and the medulla: neuromyelitis optica spectrum disorder presenting as area postrema syndrome. <i>Postgraduate Medical Journal</i> , 2018, 94, 724-724.	1.8	1
196	Neurological Disease in Lupus: Toward a Personalized Medicine Approach. <i>Frontiers in Immunology</i> , 2018, 9, 1146.	4.8	36
197	An Overview of Autoimmune and Paraneoplastic Encephalitides. <i>Seminars in Neurology</i> , 2018, 38, 330-343.	1.4	25
198	Neuromyelitis Optica Spectrum Disorders. , 2018, , 313-335.		1
199	Treating neuromyelitis optica with azathioprine: 20-year clinical practice. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1150-1161.	3.0	27
200	Clinical features and prognoses of acute transverse myelitis in patients with systemic lupus erythematosus. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 442-451.	1.7	11
201	Neuromyelitis Optica Spectrum Disorders. , 2019, , 187-195.		0
202	Acute Demyelinating Disorders in the Neurocritical Care Unit. , 2019, , 414-420.		0
203	Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. <i>Journal of Neuroinflammation</i> , 2019, 16, 134.	7.2	115
205	Spinal cord syndromes in patients with systemic lupus erythematosus: differentiating lupus myelitis, neuromyelitis optica, and multiple sclerosis. <i>Lupus</i> , 2019, 28, 1656-1662.	1.6	16
206	Letter to the Editor - Late-onset neuromyelitis optica associated with cryptogenic organizing pneumonia. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 36, 101398.	2.0	6

#	ARTICLE	IF	CITATIONS
207	Herpes Simplex Virus Type 2 Radiculomyelitis Disguised as Conversion Disorder. Case Reports in Neurology, 2019, 11, 117-123.	0.7	5
209	Suspected bacterial meningoencephalomyelitis as the trigger or presentation of neuromyelitis optica spectrum disorder flare. Multiple Sclerosis and Related Disorders, 2019, 30, 38-41.	2.0	9
210	Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis. Multiple Sclerosis and Related Disorders, 2019, 33, 22-32.	2.0	47
211	Disease course, progression and activity of neuromyelitis optica (NMOSD) in patients who were treated with Rituximab, 6 and 12 months after receiving the first dose of drug, in Isfahan city. Multiple Sclerosis and Related Disorders, 2019, 34, 77-82.	2.0	7
212	Differential Diagnosis of Pediatric Multiple Sclerosis. Children, 2019, 6, 75.	1.5	5
213	Epidemiology of NMOSD in Sweden from 1987 to 2013. Neurology, 2019, 93, e181-e189.	1.1	51
214	Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review. Journal of Neuroimmunology, 2019, 332, 126-134.	2.3	14
215	Neuromyelitis optica spectrum disorder in a tertiary hospital in the Philippines: a case series. Multiple Sclerosis and Related Disorders, 2019, 31, 124-130.	2.0	6
216	Plasma exchange: an effective add-on treatment of optic neuritis in neuromyelitis optica spectrum disorders. International Ophthalmology, 2019, 39, 2477-2483.	1.4	24
219	Autonomic dysfunction in people with neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2020, 26, 688-695.	3.0	13
220	Review: Recent advances in the understanding of the pathophysiology of neuromyelitis optica spectrum disorder. Neuropathology and Applied Neurobiology, 2020, 46, 199-218.	3.2	33
221	Ocular manifestations in celiac disease: an overview. International Ophthalmology, 2020, 40, 1049-1054.	1.4	17
222	Efficacy and safety of azathioprine for neuromyelitis optica spectrum disorders: A meta-analysis of real-world studies. Multiple Sclerosis and Related Disorders, 2020, 46, 102484.	2.0	12
223	Sequential intermittent therapeutic plasma exchange: A possible induction and maintenance therapy in the management of adult patients with neuromyelitis optica spectrum disorder. Therapeutic Apheresis and Dialysis, 2020, 25, 513-532.	0.9	5
224	NMOSD acute attack: Understanding, treatment and innovative treatment prospect. Journal of Neuroimmunology, 2020, 348, 577387.	2.3	22
225	Predictive Factors of Resistance to High-Dose Steroids Therapy in Acute Attacks of Neuromyelitis Optica Spectrum Disorder. Frontiers in Neurology, 2020, 11, 585471.	2.4	6
226	Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice. Multiple Sclerosis and Related Disorders, 2020, 45, 102428.	2.0	42
227	Differential Effects of MS Therapeutics on B Cellsâ€™ Implications for Their Use and Failure in AQP4-Positive NMOSD Patients. International Journal of Molecular Sciences, 2020, 21, 5021.	4.1	20

#	ARTICLE	IF	CITATIONS
228	Biologic Therapy in Refractory Non-Multiple Sclerosis Optic Neuritis Isolated or Associated to Immune-Mediated Inflammatory Diseases. A Multicenter Study. Journal of Clinical Medicine, 2020, 9, 2608.	2.4	3
229	<p>Prognostic Factors for Visual Outcomes Following the First Episode of NMOSD-Related Optic Neuritis in Affected Eyes</p>. Clinical Ophthalmology, 2020, Volume 14, 4271-4278.	1.8	9
230	Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies. Frontiers in Neurology, 2020, 11, 778.	2.4	37
231	Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2020, 19, 298-306.	10.2	218
232	Retrospective Observation of Low-Dose Rituximab Treatment in Chinese Patients With Neuromyelitis Optica Spectrum Disorders in a Real-World Setting. Frontiers in Neurology, 2020, 11, 642.	2.4	13
233	Treatment of MOG antibody associated disorders: results of an international survey. Journal of Neurology, 2020, 267, 3565-3577.	3.6	64
234	Astrocytes Are Required for Oligodendrocyte Survival and Maintenance of Myelin Compaction and Integrity. Frontiers in Cellular Neuroscience, 2020, 14, 74.	3.7	37
235	Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurology, The, 2020, 19, 391-401.	10.2	183
236	The nervous system in systemic lupus erythematosus. , 2021, , 469-478.		0
237	Neuromyelitis optica spectrum disorders. Journal of the Neurological Sciences, 2021, 420, 117225.	0.6	29
238	Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders. BioDrugs, 2021, 35, 7-17.	4.6	11
239	Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment. Eye, 2021, 35, 753-768.	2.1	35
240	Persistently Gadolinium-Enhancing Lesion Is a Predictor of Poor Prognosis in NMOSD Attack: a Clinical Trial. Neurotherapeutics, 2021, 18, 868-877.	4.4	6
241	Strategies to Aid Identification of Apheresis PowerFlow Ports: A Case Report. Journal of Emergency Nursing, 2021, 47, 21-27.	1.0	4
242	Serum Tumor Markers in Paraneoplastic Neurologic Syndromes: A Systematic Review of Guidelines. Frontiers in Neurology, 2020, 11, 607553.	2.4	2
243	Remedial Effect of Intravenous Cyclophosphamide in Corticosteroid-Refractory Patients in the Acute Phase of Neuromyelitis Optica Spectrum Disorder-Related Optic Neuritis. Frontiers in Neurology, 2020, 11, 612097.	2.4	6
244	B Cells and Antibodies as Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders. Pharmaceuticals, 2021, 14, 37.	3.8	6
245	Intravenous immunoglobulin as the rescue treatment in NMOSD patients. Neurological Sciences, 2021, 42, 3857-3863.	1.9	10

#	ARTICLE	IF	CITATIONS
246	Central nervous system demyelinating diseases in Hong Kong. <i>Neurology and Clinical Neuroscience</i> , 2021, 9, 292-300.	0.4	3
247	Meningitis as a recurrent manifestation of anti-AQP4/anti-MOG negative neuromyelitis optica spectrum disorder: a case report. <i>BMC Neurology</i> , 2021, 21, 109.	1.8	3
248	Neuromyelitis Optica Spectrum Disorder Treatmentâ€”Current and Future Prospects. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2801.	4.1	13
249	New Therapeutic Landscape in Neuromyelitis Optica. <i>Current Treatment Options in Neurology</i> , 2021, 23, 13.	1.8	11
250	Longitudinally Extensive Transverse Myelitis: A Retrospective Study Differentiating Neuromyelitis Optica Spectrum Disorder From Other Etiologies. <i>Cureus</i> , 2021, 13, e13968.	0.5	0
251	Neuromyelitis Optica Spectrum Disorders (NMOSD) and Connective Tissue Disease (CTD): an Update for the Rheumatologist. <i>Current Rheumatology Reports</i> , 2021, 23, 33.	4.7	16
252	CNS autoimmunity in children: An unwanted wrinkle in a smooth narrative. <i>Medical Journal Armed Forces India</i> , 2021, 77, 138-146.	0.8	0
253	Autoantibodies Against the Complement Regulator Factor H in the Serum of Patients With Neuromyelitis Optica Spectrum Disorder. <i>Frontiers in Immunology</i> , 2021, 12, 660382.	4.8	7
254	Targeting Neuromyelitis Optica Pathogenesis: Results from Randomized Controlled Trials of Biologics. <i>Neurotherapeutics</i> , 2021, 18, 1623-1636.	4.4	2
255	Autoimmune Neurologic Emergencies. <i>Neurologic Clinics</i> , 2021, 39, 589-614.	1.8	0
257	UNILATERAL DIAPHRAGMATIC PALSY MIMICKING A PULMONARY SPAC OCCUPYING LESION IN A CASE OF NEUROMYELITIS OPTICA. , 2021, , 46-47.		0
258	Serum neurofilament light chain and glial fibrillary acidic protein in AQP4â€”seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study. <i>Journal of Neurochemistry</i> , 2021, 159, 913-922.	3.9	11
259	Rescue immunoadsorption treatment for neuromyelitis optica spectrum disorder attacks unresponsive to intravenous methylprednisolone. <i>Journal of Neuroimmunology</i> , 2021, 356, 577604.	2.3	7
260	Establishing a second-generation artificial intelligence-based system for improving diagnosis, treatment, and monitoring of patients with rare diseases. <i>European Journal of Human Genetics</i> , 2021, 29, 1485-1490.	2.8	42
261	Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: a Meta-analysis of Randomized Control Trials. <i>Frontiers in Pharmacology</i> , 2021, 12, 652759.	3.5	7
262	Magnetic resonance imaging in neuromyelitis optica spectrum disorder. <i>Clinical and Experimental Immunology</i> , 2021, 206, 251-265.	2.6	14
263	Targeting interleukin-6 to treat neuromyelitis optica spectrum disorders: Implications from immunology, the FcRn pathway and clinical experience. <i>Drug Discovery Today</i> , 2021, 26, 1591-1601.	6.4	8
264	Systematic review of cases of acute myelitis in individuals with COVIDâ€”19. <i>European Journal of Neurology</i> , 2021, 28, 3230-3244.	3.3	31

#	ARTICLE	IF	CITATIONS
265	Therapeutic Response and Possible Biomarkers in Acute Attacks of Neuromyelitis Optica Spectrum Disorders: A Prospective Observational Study. <i>Frontiers in Immunology</i> , 2021, 12, 720907.	4.8	6
266	COVID-19 Vaccination Attitudes With Neuromyelitis Optica Spectrum Disorders: Vaccine Hesitancy and Coping Style. <i>Frontiers in Neurology</i> , 2021, 12, 717111.	2.4	9
267	Treatment of Neuromyelitis Optica Spectrum Disorders. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8638.	4.1	29
268	Efficacy of azathioprine, mycophenolate mofetil, and rituximab in the treatment of neuromyelitis optica spectrum disorder and analysis of prognostic factors. <i>Neurological Sciences</i> , 2022, 43, 2651-2658.	1.9	7
269	Physical, Emotional, Medical, and Socioeconomic Status of Patients With NMOSD: A Cross-Sectional Survey of 123 Cases From a Single Center in North China. <i>Frontiers in Neurology</i> , 2021, 12, 737564.	2.4	3
270	Management of Acute Demyelinating Attacks in the Pediatric Population: A Swiss Consensus Statement. <i>Clinical and Translational Neuroscience</i> , 2021, 5, 17.	0.9	1
271	Pruritus as an initial symptom of neuromyelitis optica spectrum disorder. A peruvian case report. <i>Neuroimmunology Reports</i> , 2021, 1, 100021.	0.4	0
273	Semiquantitative measurement of aquaporin-4 antibodies as a possible surrogate marker of neuromyelitis optica spectrum disorders with systemic autoimmune diseases. <i>Modern Rheumatology</i> , 2012, 22, 676-684.	1.8	7
275	Neuromyelitis Optica with Painful Tonic Spasms. <i>Bahrain Medical Bulletin</i> , 2015, 37, 54-56.	0.1	1
276	Systematic Review of Clinical Practice Guidelines Related to Multiple Sclerosis. <i>PLoS ONE</i> , 2014, 9, e106762.	2.5	13
280	New progress in the treatment of neuromyelitis optica spectrum disorder with monoclonal antibodies (Review). <i>Experimental and Therapeutic Medicine</i> , 2020, 21, 148.	1.8	5
281	Neuromyelitis optica spectrum disease characteristics in Isfahan, Iran: A cross-sectional study. <i>Journal of Research in Medical Sciences</i> , 2017, 22, 41.	0.9	13
282	Diagnostic modalities in multiple sclerosis: Perspectives in children. <i>Biomedical Journal</i> , 2014, 37, 50.	3.1	11
283	Role of low plasma volume treatment on clinical efficacy of plasmapheresis in neuromyelitis optica. <i>Asian Journal of Transfusion Science</i> , 2017, 11, 102.	0.3	12
284	Comprehensive review of neuromyelitis optica and clinical characteristics of neuromyelitis optica patients in Puerto Rico. , 2018, 9, 242.		16
285	Role of the clinical immunology laboratory in disease monitoring. <i>World Journal of Immunology</i> , 2013, 3, 18.	0.5	5
287	Relevance of Autoantibodies for the Classification and Pathogenesis of Neurological Diseases. , 0, , .		0
289	Infektionen. , 2012, , 483-550.		0

#	ARTICLE	IF	CITATIONS
291	Visual Disorders in Optic Neuromyelitis: Report of Two Cases. Journal of Clinical & Experimental Ophthalmology, 2013, , .	0.1	0
293	Comparing neuromyelitis optica and multiple sclerosis severity: is there a difference?. Arquivos De Neuro-Psiquiatria, 2013, 71, 271-272.	0.8	1
294	A Chinese Lady with Combine Neuromyelitis Optica and Sjögren's Syndrome: A Case Report. Journal of Neurophysiology and Neurological Disorders, 2013, , .	0.0	0
295	Diversity of Neuromyelitis Optica: Inner City Hospital Experience and Review of Literature. Journal of Neurology & Neurophysiology, 2014, 05, .	0.1	0
296	Efficacy of Plasma Exchange Therapy for Steroid-Unresponsive Neuromyelitis Optica. Journal of Korean Ophthalmological Society, 2014, 55, 465.	0.2	1
297	Longitudinal Ekstensif Transvers Miyelit: Olgu Sunumu. Sisli Etfal Hastanesi Tip Bulteni, 2014, , 146-9.	0.3	0
298	Neuromielitis Óptica en el embarazo: reporte de un caso. Revista Universitas Medica, 2016, 55, 456-465.	0.1	0
299	Infektionen. , 2015, , 505-575.		0
300	First Experience and the Effectiveness of Immunomodulating Treatment in Inflammatory Demyelinating CNS Diseases: Analysis of Nine Patients / ImānmodulājoĀs Terapijas Efektivitāte Centrālās Nervu Sistāmas Iekaisāgu Saslimājanu Gadājumos: DeviĀtu Pacientu Analāze. Proceedings of the Latvian Academy of Sciences, 2015, 69, 269-273.	0.1	0
301	Acquired Inflammatory Diseases of the Optic Nerve: From the Neuro-Ophthalmologist's Approach. , 2016, , 361-367.		0
302	Neuromyelitis Optica (Devic's Disease): A New Concept for an Old Disease. , 2016, , 351-359.		0
303	Neuromyelitis Optica Spectrum Disorders: a definite case with Autoimmune Thyroiditis. International Journal of Clinical Neurosciences and Mental Health, 2016, 3, .	0.7	0
305	Ocular Manifestations of Neurologic Diseases. , 2017, , 491-516.		0
306	Presentation of Neuromyelitis Optica with Recurrent Severe Myelitis and Acute Respiratory Failure in an Old Woman. Zahedan Journal of Researches in Medical Sciences, 2017, 19, .	0.2	0
307	Acute Disturbance/Loss of Vision. Ocular Trauma, 2018, , 57-94.	0.1	0
308	Inflammatory and Autoimmune Disorders of the Spinal Cord. , 2019, , 201-213.		0
309	NEUROMYELITIS OPTICA-A RARE CASE. Journal of Evolution of Medical and Dental Sciences, 2019, 8, 653-655.	0.1	0
310	Comparison of Bladder Dysfunction and Urinary Symptoms Between Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. Caspian Journal of Neurological Sciences, 2019, 5, 105-110.	0.2	1

#	ARTICLE	IF	CITATIONS
311	Neuromyelitis Optica Spectrum Disorder: A Case Report of Effective Combination Immunosuppressant, Corticosteroids, and Therapeutic Plasma Exchange. Open Access Macedonian Journal of Medical Sciences, 2019, 7, 3433-3436.	0.2	2
312	Overview of the Current Situation and Challenges about Neuromyelitis Optica Spectrum Disorders in the Republic of Macedonia. Open Access Macedonian Journal of Medical Sciences, 2020, 8, 40-46.	0.2	0
313	Neuromyelitis Optica Spectrum Disorders in Migrants. Sustainable Development Goals Series, 2022, , 201-212.	0.4	0
314	Neuromyelitis optica spectrum standstill in rheumatic systemic autoimmune diseases. Egyptian Rheumatology and Rehabilitation, 2020, 47, .	0.6	3
315	A descriptive study of prevalence, clinical features and other findings of neuromyelitis optica and neuromyelitis optica spectrum disorder in Khuzestan Province, Iran. Iranian Journal of Neurology, 2015, 14, 204-10.	0.5	17
316	Devic's syndrome in aquaporin-4 antibody negative patient. What we need to know â€¦. GMS Ophthalmology Cases, 2014, 4, Doc09.	0.1	0
317	Pathobiology, Diagnosis, and Current Biomarkers in Neuromyelitis Optica Spectrum Disorders. journal of applied laboratory medicine, The, 2022, 7, 305-310.	1.3	5
318	Management of Acute Demyelinating Attacks in the Pediatric Population: A Swiss Consensus Statement. Neuropediatrics, 2021, 52, .	0.6	0
319	Randomized Controlled Trials for Neuromyelitis Optica Spectrum Disorder. Neurologist, 2022, 27, 14-20.	0.7	1
320	Visual Evoked Potentials in Neuromyelitis Optica Spectrum Disorders. Journal of Central Nervous System Disease, 2021, 13, 117957352110573.	1.9	1
321	Review of a Case of Optic Neuromyelitis Spectrum Disease Complicated with Sjogrenâ€™s Syndrome. Advances in Clinical Medicine, 2022, 12, 91-94.	0.0	0
322	Possibilities of therapy for neuromyelitis optica spectrum disorders. Russkii Zhurnal Detskoi Nevrologii, 2022, 16, 49-58.	0.3	0
323	A prospective study on tryptophan immunoadsorption in AQP4 antibodyâ€”positive neuromyelitis optica spectrum disorders. Journal of Clinical Apheresis, 2022, , .	1.3	1
324	Neuromyelitis Optica Spectrum Disorder Associated with Cryptogenic Organizing Pneumonia in a Young Patient. European Journal of Case Reports in Internal Medicine, 2022, 9, 003105.	0.4	0
325	Relapsing neuromyelitis optica spectrum disorder. Journal of Dr NTR University of Health Sciences, 2021, 10, 269.	0.1	0
327	A Case of Neuromyelitis Optica: Puerto Rican Woman with an Increased Time Lag to Diagnosis and a High Response to Eculizumab Therapy. Case Reports in Neurological Medicine, 2022, 2022, 1-5.	0.4	0
328	Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD. Neurotherapeutics, 2022, 19, 808-822.	4.4	14
329	Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN-2 study): B cell monitoring-based administration. Multiple Sclerosis and Related Disorders, 2022, 60, 103730.	2.0	11

#	ARTICLE	IF	CITATIONS
330	Pediatric Neuromyelitis Optica Spectrum Disorder: Case Series and Literature Review. Life, 2022, 12, 19.	2.4	3
331	Internuclear Ophthalmoplegia Characterizes Multiple Sclerosis Rather Than Neuromyelitis Optica Spectrum Disease. Journal of Neuro-Ophthalmology, 2022, Publish Ahead of Print, .	0.8	1
332	Pain Symptoms in Optic Neuritis. Frontiers in Pain Research, 2022, 3, 865032.	2.0	4
335	Human Umbilical Cord Mesenchymal Stem Cells to Treat Neuromyelitis Optica Spectrum Disorder (hUCâ€“MSCâ€“NMOSD): A Study Protocol for a Prospective, Multicenter, Randomized, Placebo-Controlled Clinical Trial. Frontiers in Neurology, 2022, 13, 860083.	2.4	4
336	Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patientsâ€™ Perspective: An Observational Cross-Sectional Study. Neurology and Therapy, 2022, 11, 1101-1116.	3.2	3
337	Optic neuritis with potential for poor outcome. Practical Neurology, 2022, , practneurol-2021-003228.	1.1	0
338	Disease Course and Outcomes in Patients With the Limited Form of Neuromyelitis Optica Spectrum Disorders and Negative AQP4-IgG Serology at Disease Onset: A Prospective Cohort Study. Journal of		

#	ARTICLE	IF	CITATIONS
350	Kaleidoscopic nervous system involvement in the setting of a chronic multisystem dysimmune disorder: report of a remarkable case. Romanian Journal of Neurology/ Revista Romana De Neurologie, 2013, 12, 70-86.	0.1	2
351	Az autoantitest-vizsgálatok jelentősége szisztémás lupus erythematosusban. Orvosi Hetilap, 2022, 163, 1695-1703.	0.4	1
352	Neuromyelitis optica: Clinical course and potential prognostic indicators. Multiple Sclerosis and Related Disorders, 2023, 69, 104414.	2.0	3
353	Plasmapheresis for Neuromyelitis Optica: A Review from the Transfusion Medicine Specialist's Perspective. European Medical Journal Neurology, 0, , 95-101.	0.0	1
354	Consensus opinion on the management of patients with neuromyelitis optica spectrum diseases: issues of terminology and therapy. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2022, 14, 139-148.	1.2	4
355	A RARE CASE NEUROMYELITIS OPTICA SPECTRUM DISORDER. , 2022, , 86-87.		0
356	Predictors for Acute Respiratory Failure in AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorders Patients with Medullary Lesions. SSRN Electronic Journal, 0, , .	0.4	0
357	Comparison of clinico-radiological profile, optical coherence tomography parameters, and outcome in MOGAD and Neuromyelitis optica spectrum disorder subtypes: A prospective observational study. Journal of Neurosciences in Rural Practice, 0, , .	0.8	1
358	Understanding Treatment Decisions in Neuromyelitis Optica Spectrum Disorder: A Global Clinical Record Review with Patient Interviews. Neurology and Therapy, 2023, 12, 619-633.	3.2	3
359	Characterization of Disease Severity and Stability in NMOSD: A Global Clinical Record Review with Patient Interviews. Neurology and Therapy, 2023, 12, 635-650.	3.2	3
361	Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis optica spectrum disorder: a Bayesian network meta-analysis. Journal of Neurology, 2023, 270, 2950-2963.	3.6	2
362	The neuro-ophthalmological manifestations of NMOSD and MOGAD—a comprehensive review. Eye, 2023, 37, 2391-2398.	2.1	3
363	Neuromyelitis Optica Spectrum Disorder: A Rare Case of Transverse Myelitis and Autonomic Dysfunction. Cureus, 2023, , .	0.5	0
365	Predictors for acute respiratory failure in AQP4-IgG-positive neuromyelitis optica spectrum disorders patients with medullary lesions. Journal of Clinical Neuroscience, 2023, 114, 131-136.	1.5	1
366	Plasma exchange for acute optic neuritis in neuromyelitis optica or neuromyelitis optica spectrum disorder: a systematic review. Annals of Medicine, 2023, 55, .	3.8	0
367	A Clinical Approach to Existing and Emerging Therapeutics in Neuromyelitis Optica Spectrum Disorder. Current Neurology and Neuroscience Reports, 2023, 23, 489-506.	4.2	1
368	Radiological identification of neuromyelitis optica in a patient presented with unexplained weight loss and generalized weakness: a case report and literature review. Annals of Medicine and Surgery, 2023, 85, 3145-3148.	1.1	0
369	A comprehensive review of the advances in neuromyelitis optica spectrum disorder. Autoimmunity Reviews, 2023, 22, 103465.	5.8	3

#	ARTICLE	IF	CITATIONS
371	Integrative analysis of purine metabolites and gut microbiota in patients with neuromyelitis optica spectrum disorders after mycophenolate mofetil treatment. BMC Neurology, 2023, 23, .	1.8	0
372	Relapses and Serious Infections in Patients with Neuromyelitis Optica Spectrum Disorder Treated with Rituximab: A Swedish Single-Center Study. Journal of Clinical Medicine, 2024, 13, 355.	2.4	0
373	Successful treatment for neuromyelitis optica with systemic lupus erythematosus. Chinese Medical Journal, 2013, 126, 3996-3997.	2.3	0
374	Combination of serum markers with optical coherence tomography angiography for evaluating neuromyelitis optica spectrum disorders and multiple sclerosis. Multiple Sclerosis and Related Disorders, 2024, 85, 105478.	2.0	0
375	Neuromyelitis optica spectrum disorder. Advances in Clinical Neuroscience & Rehabilitation: ACNR, 2017,, .	0.1	0
376	A Comparative Review of Typical and Atypical Optic Neuritis: Advancements in Treatments, Diagnostics, and Prognosis. Cureus, 2024, , .	0.5	0